Literature DB >> 7510086

Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex.

B Forghani1, L Ni, C Grose.   

Abstract

Varicella-zoster virus (VZV) glycoprotein gpIII is the homolog of herpes simplex virus gH. Through the use of panels of monoclonal antibodies, VZV gpIII is known to possess a complement-independent neutralization epitope which is conformational in nature. Monoclonal antibody to this same epitope, when added postinfection, inhibits both syncytia formation and egress of virus. The nature of the neutralization epitope was investigated to determine whether its formation was dependent on gpIII alone or required a second VZV glycoprotein. To this end, VZV ORF 37 (gH) and VZV ORF 60 (gL homolog) were cloned into a vaccinia virus-pTM1 expression system. Analyses of the transfected products demonstrated that gpIII alone was not fully glycosylated nor was it transported to the cell surface. When both ORF 37 and ORF 60 were cotransfected, the gpIII product was transported to the cell surface, where it formed a neutralization epitope recognized by a previously characterized monoclonal antibody reagent. In summary, the VZV homologs of the herpes simplex virus gH:gL complex included a M(r) 118,000 product (gpIII or gH) and a M(r) 20,000 product (ORF 60 or gL).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510086     DOI: 10.1006/viro.1994.1145

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Induction of cell-cell fusion from without by human herpesvirus 6B.

Authors:  Simon Metz Pedersen; Bodil Oster; Bettina Bundgaard; Per Höllsberg
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Pseudorabies virus glycoprotein L is necessary for virus infectivity but dispensable for virion localization of glycoprotein H.

Authors:  B G Klupp; W Fuchs; E Weiland; T C Mettenleiter
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.

Authors:  Q Li; S M Turk; L M Hutt-Fletcher
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

4.  Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.

Authors:  X Wang; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Glycoprotein H of herpes simplex virus type 1 requires glycoprotein L for transport to the surfaces of insect cells.

Authors:  D F Westra; K L Glazenburg; M C Harmsen; A Tiran; A Jan Scheffer; G W Welling; T Hauw The; S Welling-Wester
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Gene expression and in vitro replication of bovine gammaherpesvirus type 4.

Authors:  F Romeo; E Louge-Uriarte; E Gonzalez-Altamiranda; S Delgado; S Pereyra; P Morán; A Odeón; S Pérez; Andrea E Verna
Journal:  Arch Virol       Date:  2021-01-05       Impact factor: 2.574

7.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope.

Authors:  Pilailuk Akkapaiboon; Yasuko Mori; Tomohiko Sadaoka; Sayoko Yonemoto; Koichi Yamanishi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.

Authors:  X Wang; W J Kenyon; Q Li; J Müllberg; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex).

Authors:  Z Yao; C Grose
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.